Aldeyra Therapeutics, Inc. (137)
XFRA 
Summary
137 Chart
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
Aldeyra Therapeutics NASDAQ: ALDX said it plans to submit a formal dispute resolution request, or FDRR, to the FDA's Office of New Drugs seeking review of the agency's latest complete response letter for reproxalap, its investigational treatment for the signs and symptoms of dry eye disease.
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
Aldeyra Therapeutics NASDAQ: ALDX Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, following a third complete response letter tied to efficacy questions.
Aldeyra Therapeutics, Inc. (137) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aldeyra Therapeutics, Inc. ever had a stock split?
Aldeyra Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Todd C. Brady CEO | XFRA Exchange | 01438T106 CUSIP |
| US Country | 6 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Aldeyra Therapeutics, Inc. is a biotechnology enterprise focused on the invention and delivery of therapeutic solutions for immune-mediated diseases. Having begun its journey as Aldexa Therapeutics, Inc., the company underwent a rebranding in March 2014 to become Aldeyra Therapeutics, Inc. Since its establishment in 2004, and based out of Lexington, Massachusetts, it has dedicated itself to addressing the unmet needs of patients suffering from various immune-mediated conditions through the development and commercialization of novel medications.
Products and Services
- Reproxalap:
As Aldeyra Therapeutics, Inc.'s flagship product candidate, reproxalap is a pioneering RASP (Reactive Aldehyde Species) modulator presently in Phase III clinical trials. It’s specifically aimed at treating dry eye diseases, showcasing the company's innovative approach to mitigating symptoms by targeting underlying inflammation.
- ADX-629:
This orally administered RASP modulator expands the company's portfolio into the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. By regulating the body's immune response, ADX-629 represents a versatile approach with potential applications across a variety of immune-mediated diseases.
- ADX-2191:
ADX-2191 is a dihydrofolate reductase inhibitor in development for the treatment of retinitis pigmentosa and other rare retinal diseases characterized by inflammation and vision loss. It emphasizes Aldeyra’s commitment to addressing rare diseases with significant unmet medical needs.
- ADX-246 & ADX-248:
The company is also exploring the therapeutic potential of ADX-246 and ADX-248 in the realms of systemic immune-mediated disease and geographic atrophy, respectively. While specific details and trial phases are not disclosed, these products signify Aldeyra’s ongoing research and development efforts to broaden its impact on immune-mediated diseases.
Contact Information
